NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) was the recipient of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 1,100 shares, a decrease of 35.3% from the July 31st total of 1,700 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 0.5 days.

NeuroSense Therapeutics Price Performance

Shares of NRSNW opened at $0.15 on Wednesday. The stock’s 50 day moving average is $0.18 and its two-hundred day moving average is $0.23. NeuroSense Therapeutics has a twelve month low of $0.07 and a twelve month high of $0.65.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.